Trial Profile
A Randomized, Double-blinded, Placebo-controlled, Phase IIa Dose-ranging Study to Assess the Safety, Pharmacokinetics, and Tolerability of Multiple Doses of Sodium Nitrite in Diabetic Patients With Peripheral Arterial Disease (PAD) - SONIC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Apr 2023
Price :
$35
*
At a glance
- Drugs Sodium nitrite (Primary)
- Indications Diabetic complications; Peripheral arterial disorders
- Focus Adverse reactions
- Acronyms SONIC
- Sponsors TheraVasc
- 13 Apr 2023 According to a JanOne media release, Dr.Amol Soin, Chief Medical Officer of JanOne, will be presenting at the Appalachian Region Spine and Pain Meeting in Sulfur Springs, West Virginia on Sat, Apr 15 on the topic of Innovation in Pain Medicine and will be discussing the drug development programs (JAN 101 and JAN123) at JanOne.
- 16 Sep 2020 According to a JanOne media release, JAN101 demonstrated positive results in this trial.
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.